TRANSCRIPTIONAL PROGRAMS OF MONOCYTE-DERIVED TOLEROGENIC DENDRITIC CELLS FROM RHEUMATOID ARTHRITIS PATIENTS AND HEALTHY SUBJECTS OBTAINED BY MODULATION WITH DEXAMETHASONE AND MONOPHOSPHORYL LIPID A

2016 ◽  
Author(s):  
Juan Carlos Aguillón
Keyword(s):  
Rheumatoid Arthritis ◽  
Dendritic Cells ◽  
Healthy Subjects ◽  
Lipid A ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Tolerogenic Dendritic Cells

Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy

Vaccine ◽  
2012 ◽  
Vol 30 (2) ◽  
pp. 378-387 ◽  
Author(s):  
Dàlia Raïch-Regué ◽  
Mar Naranjo-Gómez ◽  
Laia Grau-López ◽  
Cristina Ramo ◽  
Ricardo Pujol-Borrell ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Lipid A ◽  
Differential Effects ◽  
Cytokine Cocktail ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Tolerogenic Dendritic Cells

scholarly journals A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines

2013 ◽  
Vol 11 (1) ◽  
pp. 128 ◽  
Author(s):  
Paulina García-González ◽  
Rodrigo Morales ◽  
Lorena Hoyos ◽  
Jaxaira Maggi ◽  
Javier Campos ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Lipid A ◽  
Monophosphoryl Lipid A ◽  
Migratory Capacity ◽  
Monophosphoryl Lipid ◽  
Tolerogenic Dendritic Cells

scholarly journals Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4+ T Cells

2016 ◽  
Vol 7 ◽  
Author(s):  
Jaxaira Maggi ◽  
Katina Schinnerling ◽  
Bárbara Pesce ◽  
Catharien M. Hilkens ◽  
Diego Catalán ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Cd4 T Cells ◽  
Lipid A ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Memory Cd4 T Cells

Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ–matured type I dendritic cells for immunotherapy

Cytotherapy ◽  
2014 ◽  
Vol 16 (6) ◽  
pp. 826-834 ◽  
Author(s):  
Sonja T.H.M. Kolanowski ◽  
Lathees Sritharan ◽  
Suzanne N. Lissenberg-Thunnissen ◽  
Gijs M.W. Van Schijndel ◽  
S. Marieke Van Ham ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Lipid A ◽  
Interferon Γ ◽  
Type I ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Serum Supplementation

scholarly journals Monophosphoryl Lipid A Activates Both Human Dendritic Cells and T Cells

2002 ◽  
Vol 168 (2) ◽  
pp. 926-932 ◽  
Author(s):  
Jamila Ismaili ◽  
Joëlle Rennesson ◽  
Ezra Aksoy ◽  
Johan Vekemans ◽  
Benoit Vincart ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Lipid A ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Human Dendritic Cells

scholarly journals Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential

2010 ◽  
Vol 59 (8) ◽  
pp. 1185-1195 ◽  
Author(s):  
Anja ten Brinke ◽  
Gijs van Schijndel ◽  
Remco Visser ◽  
Tanja D. de Gruijl ◽  
Jaap Jan Zwaginga ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Lipid A ◽  
Cytotoxic T Cells ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid

scholarly journals Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis

2010 ◽  
Vol 69 (11) ◽  
pp. 2042-2050 ◽  
Author(s):  
Rachel A Harry ◽  
Amy E Anderson ◽  
John D Isaacs ◽  
Catharien M U Hilkens
Keyword(s):  
Rheumatoid Arthritis ◽  
Quality Control ◽  
T Cells ◽  
Dendritic Cells ◽  
Experimental Treatment ◽  
Immunosuppressive Drugs ◽  
Interleukin 17 ◽  
Proinflammatory Mediators ◽  
Monophosphoryl Lipid A ◽  
Tolerogenic Dendritic Cells

ObjectivesTolerogenic dendritic cells (tolDCs) constitute a promising experimental treatment for targeting autoreactive T cells in autoimmune diseases, including rheumatoid arthritis (RA). The authors' goal is to bring tolDC therapy for RA to the clinic. Here the authors address key translational issues related to the manufacturing of tolDCs from RA patients with current good manufacturing practice (cGMP)-compliant reagents, the stability of tolDCs, and the selection of suitable quality control markers.MethodsHuman monocyte-derived tolDCs were established from RA patients and healthy controls (HCs) using the immunosuppressive drugs dexamethasone and vitamin D3, and the cGMP-grade immunomodulator, monophosphoryl lipid A, in the cGMP-compliant medium, CellGroDC. The functionality of tolDCs and tolDC-modulated autologous CD4 T cells was determined by flow cytometry, [3H]thymidine incorporation and ELISA.ResultsClinical-grade tolDCs established from patients with RA exhibit a typical tolerogenic phenotype of reduced costimulatory molecules, low production of proinflammatory cytokines and impaired stimulation of autologous antigen-specific T cells, comparable to HC tolDCs. Toll-like receptor 2 (TLR-2) was highly expressed by tolDCs but not mature DCs. Furthermore, tolDCs suppressed mature DC-induced T cell proliferation, interferon γ and interleukin 17 production, and rendered T cells hyporesponsive to further stimulation. Importantly, tolDCs were phenotypically stable in the absence of immunosuppressive drugs and were refractory to further challenge with proinflammatory mediators.ConclusionstolDCs established from patients with RA are comparable to those derived from healthy donors. TLR-2 was identified as an ideal marker for quality control of tolDCs. Potently tolerogenic and highly stable, these tolDCs are a promising cellular therapeutic for tailored immunomodulation in the treatment of RA.

Sign in / Sign up

Export Citation Format

Share Document